When are Atrium Therapeutics, Inc. (RNA) earnings?

AlphaOS tracks the latest reported quarter and upcoming earnings context for Atrium Therapeutics, Inc. (RNA) on the earnings intelligence page. Dates and figures update as IR and filing data land — always verify against the company's official calendar.

Did RNA beat earnings estimates?

AlphaOS surfaces beat/miss versus consensus where available, alongside YoY growth and guidance context for Atrium Therapeutics, Inc.. Open the earnings tab for the structured scorecard and AI-assisted analysis.

Where can I read RNA earnings analysis?

AlphaOS publishes structured earnings intelligence for Atrium Therapeutics, Inc. (RNA) — results, guidance, and connected research — for education only, not investment advice.

RNA

Atrium Therapeutics, Inc.

Healthcare · Biotechnology

$12.84Aug 14, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

78% confidence

Why it matters

Atrium Therapeutics, Inc. shows accelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.

Why it matters: Milestone Payment Received.

Watch: Clinical trial success risk for ATR 1072 and ATR 1086.

TrajectoryAccelerating

ExecutionMixed

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Milestone Payment Received
Pipeline Advancement
Strong Cash Position
Atrium Therapeutics Public Launch
Milestone Payment from BMS
ATR 1072 IND Submission

Risks

Clinical trial success risk for ATR 1072 and ATR 1086 · medium
Reliance on collaboration payments for significant revenue · medium

Priorities

Building Research Capabilities · In progress
Advancing ATR 1072 Program · In progress
Developing ATR 1086 · In progress

Supporting evidence

LedgerSignificant collaboration revenue from BMS milestone
LedgerStrong quarter based on: Significant collaboration revenue from BMS milestone · Advancement of ATR 1072 towards IND submission · Initiation of IND-enabling studies for ATR 1086 · Solid cash and cash e…
EventMilestone Payment Received

EventPipeline Advancement
EventStrong Cash Position
EventEstablished Atrium as a standalone entity with its own public listing and strategic direction.
EventProvides significant revenue and validates the collaboration with BMS and the progress of Atrium's development pipeline.
EventCrucial step towards initiating clinical trials for ATR 1072, a potential treatment for PRKAG2 syndrome.
InitiativeReflected in R&D expenses for Q1 2026.
InitiativeGLP toxicology studies completed; initial discussions with FDA and Health Canada completed; IND submission planned for H2 2026; Phase 1/2 clinical trial initiation planned.
InitiativeIND-enabling studies initiating in 2026.
EventClinical trial success risk for ATR 1072 and ATR 1086
EventReliance on collaboration payments for significant revenue

Pipeline evidence · 0d ago

Latest earnings · Q1 2026

Full RNA earnings analysis

Reported figures for Atrium Therapeutics, Inc. — research only, not investment advice.

Revenue YoY: +1151.0%
Intel score: 83

Theme: Clinical Development

Latest Intelligence

Updated August 15, 2026

What happened recently for Atrium Therapeutics, Inc. (RNA) — events, not interpretation.

Event: Reported Q1 2026 revenue +1151% YoY.
Also: Last session August 14, 2026 at $12.84.
Source: Q1 2026 earnings

Research & analysis only — not investment advice.

Loading earnings intelligence…

Atrium Therapeutics, Inc. (RNA)

Healthcare · Biotechnology

Investment Snapshot above is the primary AlphaOS analysis for Atrium Therapeutics, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:: Healthcare
Industry:: Biotechnology
Market cap:: $219.64M
Revenue:: $19.64M

RNA earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Related & Connected

Opening stock page...

Fetching company snapshot, pricing, and intelligence.

RNA

Investment Snapshot

Why it matters

Key signals

Risks

Priorities

Supporting evidence

Latest earnings · Q1 2026

Latest Intelligence

Atrium Therapeutics, Inc. (RNA)

Key facts

Related & Connected

Related

RNA

Investment Snapshot

Why it matters

Key signals

Risks

Priorities

Supporting evidence

Latest earnings · Q1 2026

Latest Intelligence

Atrium Therapeutics, Inc. (RNA)

Key facts

Related & Connected

Related

Connected intelligence

Themes